CME ACCREDITATION AND DESIGNATION
The Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cardiovascular Research Foundation designates this activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Documentation of awarded credit is provided for participants in exchange for completed activity evaluations.
OVERVIEW
Pretreatment of patients undergoing percutaneous coronary intervention has been controversial. The decision to use P2Y12 Inhibitors has been the cornerstone treatment of patients with acute coronary syndrome. This program will look at the correct timing and modality of transition from intravenous to oral platelet inhibition in patients. Considerations for platelet inhibition before, during, and after PCI and the outcomes of establishing potent P2Y12 inhibition with medication will be discussed. DAPT selection and duration as well as bridging antiplatelet coverage will be reviewed. Experts in the field will also share tips to help the practitioner with the transition to oral P2Y12 receptor blockades. The program will wrap up with time for Q&A with the presenters.
LEARNING OBJECTIVES
By the end of this program, participants should be able to:
1) Discuss the appropriate circumstances for use of potent intravenous P2Y12 inhibition.
2) Explain considerations for DAPT use in patients at high risk for bleeding and ischemia as well as DES patients with atrial fibrillation.
3) Describe when antiplatelet monotherapy should be used.
TARGET AUDIENCE
This activity is designed for interventional cardiologists, cardiac surgeons, clinical cardiologists, vascular medicine specialists, and other healthcare professionals.
ACTIVITY EVALUATION
Evaluation by questionnaire will address content, presentation, possible bias, and future educational needs.
DISCLOSURE STATEMENT
It is the policy of the Cardiovascular Research Foundation to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and, therefore, does not compromise the scientific integrity of the educational activity.
Discussion of off-label product usage and/or off-label product use is made at the sole discretion of the faculty. Off-label product discussion and usage is not endorsed by the Cardiovascular Research Foundation or the conference directors of this activity.
Faculty participating in continuing medical education activities sponsored by the Cardiovascular Research Foundation are required to disclose to the activity audience any real or apparent conflicts of interest related to the content of their presentations. Faculty not complying with this policy are not permitted to participate in this activity.
FACULTY DISCLOSURE SUMMARY
KEY: (G/R) Grant Support/Research Contract (C/H/S) Consultant Fee/Honoraria/Speaker’s Bureau (E) Equity (R/I) Royalty/Intellectual Property Rights (S) Salary/Salary Support (O) Other Financial Benefit
Dominick J. Angiolillo: (G/R) (C/H/S) AstraZeneca, Bristol-Myers Squibb, Sanofi-Aventis, Portola Pharmaceuticals, Merck/Schering Plough, Daiichi-Sankyo/Eli Lilly and Company, Chiesi
Deepak L. Bhatt: (G/R) Abbott Vascular, AstraZeneca, Daiichi-Sankyo/Eli Lilly and Company, Medtronic, Sanofi-Aventis, The Medicines Company, Chiesi, Amarin, Amgen, Idorsia, PhaseBio, Pfizer, Regeneron, Ironwood, Ischemix, Synaptic, (O) Bayer AG, St. Jude Medical, Boehringer Ingelheim
Gregg W. Stone: (C/H/S) Claret , Ablative Solutions , Matrizyme, Miracor, Neovasc, V wave , Shockwave, Valfix, Therox, REVA, Vascular Dynamics, Robocath, HeartFlow, W.L. Gore & Associates, (E) Ancora, Cagent, Qool Therapeutics, Aria, Caliber, SpectraWave, Biostar family of funds, Medfocus family of funds
Pascal Vranckx: Nothing to Disclose
Planning Committee
Robert Blanco (Planner)
(S) Cardiovascular Research Foundation
ACTIVITY SPONSORSHIP AND SUPPORT
This program is sponsored by the Cardiovascular Research Foundation. It is supported through an educational grant from Chiesi and was developed without influence from commercial supporters.
HOW TO RECEIVE CME CREDIT
To obtain CME credit for this activity, participants must review all CME information, view all presentations in their entirety, and complete the Activity Evaluation Form. If you have any questions, please contact Robert Blanco at rblanco@crf.org .